Skip to main content
Log in

A randomised, multinational study with sequential therapy comparing ciprofloxacin twice daily and ofloxacin once daily

Randomisierte, multinationale Studie mit einer sequentiellen Therapie, die Ciprofloxacin zweimal täglich mit Ofloxacin einmal täglich vergleicht

  • Originalia
  • Published:
Infection Aims and scope Submit manuscript

Summary

In a multinational, open, randomised, controlled clinical study, 474 hospitalised patients with moderate or severe infections were treated with sequential regimens of ofloxacin or ciprofloxacin. Ofloxacin 400 mg once daily or ciprofloxacin 200 mg twice daily were given intravenously for at least 3 days followed by oral treatment with ofloxacin 400 mg once daily or ciprofloxacin 500 mg twice daily. Overall cure rates of 86.8% (85.7%) in the ofloxacin group and 89.6% (89.5%) in the ciprofloxacin group were achieved in the intention-to-treat analysis (per protocol analysis). The overall bacteriological response rate (ofloxacin 89.5%, ciprofloxacin 89.0%) was comparable to the clinical cure rate. Both drugs were well tolerated and adverse events were rarely observed. It is concluded that ofloxacin and ciprofloxacin can be used successfully in the treatment of hospitalised patients with aerobic gram-positive and gram-negative infections. Ofloxacin has the advantage of a oncedaily regimen, compared to the twice-daily regimen with ciprofloxacin.

Zusammenfassung

In einer multinationalen, offenen, randomisierten, kontrollierten klinischen Studie wurden 474 hospitalisierte Patienten mit mittelschweren oder schweren Infektionen mit einer sequentiellen Therapie behandelt. Für mindestens 3 Tage wurde Ofloxacin 400 mg 1× täglich oder Ciprofloxacin 200 mg 2× täglich intravenös verabreicht. Anschließend wurde die Therapie oral fortgesetzt mit 400 mg Ofloxacin 1× täglich oder 500 mg Ciprofloxacin 2× täglich. Die Heilungsrate betrug 86,8% (85,7%) in der Ofloxacin- und 89,6% (89,5%) in der Ciprofloxacin-Gruppe in der „intention-to-treat“-Analyse („per-protocol“-Analyse). Die bakteriologische Wirksamkeit (Ofloxacin 89,5%, Ciprofloxacin 89,0%) war der klinischen Heilungsrate vergleichbar. Nebenwirkungen wurden selten beobachtet, die Verträglichkeit der beiden Therapien war gut. Die Ergebnisse haben gezeigt, daß Ofloxacin und Ciprofloxacin erfolgreich in der Behandlung hospitalisierter Patienten mit grampositiven (Aerobier) und gramnegativen Infektionen eingesetzt werden kann. Ofloxacin hat den Vorteil der Einmalgabe, Ciprofloxacin muß 2× am Tag verabreicht werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Lockley, M. R., Wise, R., Dent, J. The pharmacokinetics and tissue penetration of ofloxacin. J. Antimicrob. Chemother. 14 (1984) 647–652.

    PubMed  Google Scholar 

  2. Vance-Bryan, K., Guay, D. R. P., Rotschafer, J. C. Clinical pharmacokinetics of ciprofloxacin. Clin. Pharmacokinet. 19 (1990) 434–461.

    PubMed  Google Scholar 

  3. Wolfson, J. S. Quinolone antimicrobial agents: adverse effects and bacterial resistance. Eur. J. Clin. Microbiol. Infect. Dis. 8 (1989) 1080–1092.

    PubMed  Google Scholar 

  4. Paton, J. H., Reeves, D. S. Clinical features and management of adverse effects of quinolone antibacterials. Drug Safety 6 (1991) 8–27.

    PubMed  Google Scholar 

  5. Hooper, D., Wolfson, J. Fluoroquinolone antimicrobial agents. N. Engl. J. Med. 324 (1991) 384–394.

    PubMed  Google Scholar 

  6. Neu, H. C. Quinolone antimicrobial agents. Ann. Rev. Med. 43 (1992) 465–486.

    PubMed  Google Scholar 

  7. Farrington, C. P., Manning, G. Test statistics and sample size formula for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat. Med. 9 (1990) 1447–1454.

    PubMed  Google Scholar 

  8. Naber, K. G., Sigl, G. Fleroxacin versus ofloxacin in patients with complicated urinary tract infection: a controlled clinical study. Am. J. Med. 94 (Suppl. 3A) (1993) 114S-117S.

    PubMed  Google Scholar 

  9. Kromann-Andersen, B., Sommer, P., Pers, C., Larsen, V., Rasmussen, F.: Efficacy and safety of ofloxacin and ciprofloxacin in complicated urinary tract infection. 15th International Congress of Chemotherapy, July 19–24, 1987, Istanbul/Turkey. In: Advances in experimental and clinical chemotherapy, ecomed 3/88 (1987) pp. 45–47.

  10. Chrysanthopoulos, C. J., Skoutelis, A. T., Starakis, J. C., Arvaniti, A., Bassaris, H. P. Use of ciprofloxacin in biliary sepsis. Infection 4 (1988) 249.

    Google Scholar 

  11. Thys, J. P., Jacobs, F., Byl, B. Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 304–315.

    PubMed  Google Scholar 

  12. Gentry, L. O., Ramirez-Ronda, C. H., Rodriguez-Noriega, E., Thadepalli, H., del Rosal, P. L., Ramirez, C. Oral ciprofloxacin vs. parenteral cefotaxime in the treatment of difficult skin and skin structure infections. Arch. Intern. Med. 149 (1989) 2579–2583.

    PubMed  Google Scholar 

  13. Gentry, L. O., Rodriguez-Gomez, G., Zeluff, B. J., Koshdel, A., Price, M. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am. J. Med. 87 (Suppl. 6 C) (1989) 57S-60S.

    Google Scholar 

  14. Rahm, V., Schacht, P. Safety of ciprofloxacin: a review. Scand. J. Infect. Dis. 16 (Suppl.) (1989) 120–128.

    Google Scholar 

  15. Zaudig, M., von Bose, M., Weber, M. M., Bremer, D., Zieglgansberger, W. Psychotaxic effects of ofloxacin. Pharmacopsychiatry 22 (1989) 11–15.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bassaris, P., Akalin, E., Calangu, S. et al. A randomised, multinational study with sequential therapy comparing ciprofloxacin twice daily and ofloxacin once daily. Infection 23, 227–233 (1995). https://doi.org/10.1007/BF01781203

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01781203

Keywords

Navigation